Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.42 USD | +1.91% | -0.55% | +1.05% |
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The company is one of the best yield companies with high dividend expectations.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- One of the major weak points of the company is its financial situation.
- The company benefits from high valuations in earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialized REITs
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.05% | 3.34B | C+ | ||
+11.87% | 60.31B | A- | ||
-3.54% | 13.44B | A | ||
+2.64% | 7.78B | B | ||
-9.17% | 5.92B | B- | ||
+13.40% | 3.61B | C- | ||
-5.18% | 3.07B | B+ | ||
+2.65% | 3.03B | C | ||
+16.33% | 2.82B | C- | ||
-15.27% | 2.41B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SBRA Stock
- Ratings Sabra Health Care REIT, Inc.